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predominantly utilizes Myd88-independent signaling cascades.
Physiol Genomics 19: 319–330, 2004. First published September 14,
2004; doi:10.1152/physiolgenomics.00128.2004.—Myeloid differen-
tiation protein-88 (MyD88) is a signal adaptor protein required for
cytokine production following engagement of Toll-like receptors
(TLRs) by their cognate ligands. Activation of both TLR-3 and
TLR-4, however, can engage signaling events independent of MyD88
expression. The relative importance of these MyD88-dependent and
-independent signaling pathways in the macrophage response to
lipopolysaccharide (LPS) is unknown. Here we define these events
using microarray expression profiling of LPS-stimulated macrophages
taken from MyD88-null and wild-type mice. Of the 1,055 genes found
to be LPS responsive, only 21.5% were dependent on MyD88 expres-
sion, with MyD88-independent genes constituting 74.7% of the ge-
netic response. This MyD88-independent gene expression was pre-
dominantly transcriptionally regulated, as it was unaffected by cyclo-
heximide blockade of new protein synthesis. A previously undescribed
group of LPS-regulated genes (3.8%), whose induction or repression was
significantly greater in the absence of MyD88, was also identified by
these studies. The regulation of these genes suggested that MyD88 could
serve as a molecular brake, constraining gene activity in a subset of
LPS-responsive genes. The findings generated with LPS stimulation were
recapitulated by exposure of macrophages to live Escherichia coli. These
expression-profiling studies redefine the current dogma of TLR-4 signal-
ing and establish that MyD88, although essential for some of the best-
characterized macrophage responses to LPS, is not required for the
regulation of the majority of genes engaged by macrophage exposure to
endotoxin or live bacteria.
monocytes/macrophages; lipopolysaccharide; gene regulation; signal
transduction; cellular activation
THE ACTIVATION OF THE INNATE immune response by infectious
microorganisms requires the integration of complex networks
of signal transduction pathways, leading to the induction of
specific sets of genes (18). Toll-like receptors (TLRs) have
emerged as a major recognition and signaling component of the
mammalian host defense. TLRs recognize molecular products
derived from all the major classes of microbes including
bacteria, viruses, yeast, and fungi. Elucidating the cellular
responses following the activation of individual TLRs is fun-
damental to our understanding of innate immunity.
TLR superfamily members share a conserved Toll/interleu-
kin-1 resistance (TIR) domain, which is also present in the
interleukin-1 receptor (IL1R) and related proteins, such as
SIGIRR and ST2 (27, 48). Engagement of these receptors by
their respective ligands allows the recruitment of one or more
TIR domain-containing adapter molecules. These adapters,
myeloid differentiation protein-88 (MyD88), Mal (also known
as TIRAP), TRIF (also known as TICAM-1), or TRAM (also
known as TIRP, TICAM2), provide a structural platform for
the recruitment of kinases and downstream effector molecules
(for a complete review see Refs. 31, 47). The complex signal-
ing network initiated by the TIR domain-mediated interaction
of TLRs and adapter proteins ultimately dictates the distinct
pattern of gene expression that one observes in response to
different TLR agonists.
MyD88, the first TIR-domain adapter molecule to be de-
scribed, is essential for signaling by all IL1R/TLR family
members with the exception of TLR-3 (15, 33). The recruit-
ment of MyD88 to oligomerized TIR domains engages NF-B
and MAPK signaling cascades, resulting in the expression of
proinflammatory cytokines, such as TNF (5, 19, 32). Consis-
tent with these observations, the production of TNF is im-
paired in MyD88-deficient macrophages following stimulation
by various TLR ligands or IL-1 (1, 23). Although MyD88
initially appeared to be required for signal transduction events
engaged by TLR activation, certain TLR agonists, such as
lipopolysaccharide (LPS), have been shown to generate signals
in the absence of MyD88. These responses include the upregu-
lation of costimulatory molecules on dendritic cells (22),
caspase-1-dependent release of IL-18 (38), and expression of
type I interferons (IFN-) and interferon-stimulated genes
(24). To clarify the role of MyD88, we set out to determine the
relative contribution of MyD88-dependent and -independent
signaling events in the totality of macrophage responses to
endotoxin or live Escherichia coli. To accomplish this, we
conducted genome-wide expression profiling experiments in
macrophages taken from MyD88-null and wild-type (WT)
mice. Surprisingly, we found that the preponderance of LPS or
E. coli-responsive genes was regulated by the MyD88-inde-
pendent signaling network. Although the MyD88-independent
genes include many that are known to be important mediators
of innate immunity, a large group of genes in this class are of
unknown function. These findings indicate that recently iden-
tified adaptor molecules, other than MyD88, that lie down-
stream of TLR-4 play a more important role in the response to
Article published online before print. See web site for date of publication
(http://physiolgenomics.physiology.org).
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bacterial engagement by macrophages than was previously
recognized.
EXPERIMENTAL PROCEDURES
Materials. MyD88-deficient mice were a gift from S. Akira (Osaka,
Japan) (1) and were backcrossed onto a C57BL/6 background for a
minimum of six generations, theoretically yielding mice that are
genetically 98.5% C57BL/6. LPS derived from E. coli strain
O111:B4 was purchased from Sigma, dissolved in deoxycholate, and
re-extracted by phenol:chloroform as described (14). E. coli O111:B4
(smooth strain) gram-negative bacteria were purchased from Ameri-
can Type Culture Collection (ATCC, Manassas, VA). Endotoxin-free
poly I:C was from Amersham Pharmacia (Piscataway, NJ) and was
used in the absence of lipid reagents. Sendai virus was from Charles
River Laboratories (Wilmington, MA). Malp-2 was from EMC Mi-
crocollections (Tuebingen, Germany). R-848 was from GLSynthesis
(Worcester, MA). CpG DNA 1668 ODN was from MWG Biotech,
and cycloheximide was from Sigma (St. Louis MI). The plasmids,
pCDNA3-MyD88-AU1, pEF-Bos-Trif-Flag, and NF-B-luciferase,
used in cell transfection experiments have been previously described
(10). IRF3–5D was from John Hiscott (Montreal, Quebec, Canada).
p65-HA was from Tom Maniatis (Harvard, MA). The human Vig1
promoter (450 bp) was cloned from Thp-1 genomic DNA into pGL-3
enhancer (Promega, Madison, WI).
Cell culture and RNA isolation. Mice were anesthetized with
isoflurane and then killed by cervical dislocation. Bone marrow was
isolated from 6- to 8-wk-old C57BL/6 WT and MyD88-deficient
mice. Macrophages from these marrows were cultured in DMEM
media supplemented with 10% FBS and 15% L929 conditioned media
[a source for colony-stimulating factor (CSF)-1] for 8 days. Embry-
onic fibroblasts were derived from WT or MyD88-deficient day 14
embryos by trypsinization and cultured in DMEM, 20% FCS with
antibiotics. Thioglycolate-elicited peritoneal-exudate macrophages
were cultured as described (35). All experimental procedures involv-
ing animals conformed to NIH guidelines for animal research and
have been approved by the Massachusetts General Hospital Animal
Care Committee. For mRNA expression studies by quantitative re-
verse transcriptase PCR (QRT-PCR) and microarray analysis in bone
marrow-derived macrophages (BMDMs), cells were treated at day 8
ex vivo for 2 h with 10 ng/ml LPS or live E. coli bacteria (log phase;
1 bacteria per 1 macrophage) for 2 h, and their gene expression
profiles were compared with that of mock-treated cells incubated for
the same time. Cells from four individual mice of each genotype were
used, and each mouse served as its own mock control. Total RNA for
microarray analysis and quantitative PCR was isolated with TRIzol
reagent (Invitrogen, Carlsbad, CA) and RNeasy columns (Qiagen,
Valencia, CA). RNA quality was assessed using the 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA).
Microarray analysis. The Operon Mus musculus ver. 1.1 probe set
(Qiagen) consisting of over 13,000 oligonucleotide probes (70-mers)
was printed in the Massachusetts General Hospital (Cambridge, MA)
microarray core facility using an Omnigrid 100 (GeneMachines, San
Carlos, CA) on CodeLink activated slides (Amersham, Piscataway,
NJ). RNA was reverse transcribed and differentially labeled with Cy3
and Cy5 dyes (Amersham) using the Atlas PowerScript fluorescent
labeling kit (BD Biosciences, Palo Alto, CA). Labeled samples were
hybridized overnight using an automated hybridization station
(Genomic Solutions; Perkin-Elmer, Boston, MA). Fluorescent images
from the arrays were acquired using a microarray scanner and its
accompanying software (GenePix 4000B microarray scanner; Axon
Instruments, Union City, CA). Data was stored and further quality
controlled using the GeneTraffic software (Iobion Informatics, La
Jolla, CA) and the BioArray Software Environment (BASE) (36).
Higher-level data and statistical analysis was performed using the
GeneSpring (Silicon Genetics, Redwood City, CA) software and Gene
Expression Dynamics Inspector v. 2.0.5 (GEDI; http://web1.
tch.harvard.edu/research/ingber/GEDI/gedihome.htm) (7). For
complete microarray data sets visit the ParaBioSys web site (http://
pga.mgh.harvard.edu/) or the National Center for Biotechnology
Information (NCBI) Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/projects/geo/; accession numbers
GSE1383, GSE1384, GSE1385, and GSE1386).
QRT-PCR. Random-primed (Promega) cDNAs were generated by
reverse transcription of total RNA samples with SuperScript II (In-
vitrogen). QRT-PCR analysis was performed with an iCycler iQ
real-time PCR detection system (Bio-Rad, Hercules, CA) using 2
QuantiTect SYBR Green PCR Kit (Qiagen). Standard curves used to
determine the relative abundance of unknown samples were derived
from serially diluted gel-purified PCR products or cloned plasmids.
Data are expressed as fold changes of gene expression in LPS-treated
samples compared with mock-treated samples. The expression of
-actin was used as a control. Primers were designed using Primer3
(Whitehead Institute/MIT Center for Genome Research, Cambridge,
MA) or a public PrimerBank for PCR primers (49) (Table 1).
ELISA. BMDMs at day 8 ex vivo were plated and cultured in
96-well plates (5  104 cells/well) for 24 h prior to treatment with
MALP2 (0.01, 0.1, 1, 10 nM), poly I:C (0.1, 1, 10, 100 g/ml), LPS
(0.1, 1, 10, 100 ng/ml), R-848 (0.01, 0.1, 1, 10 M), CpG DNA
Table 1. Primers
Gene Forward Primer (5) Reverse Primer (3) cDNA Product Size, bp
Cox2 GCTGTACAAGCAGTGGCAAA GCTCGGCTTCCAGTATTGAG 318
IL-1 CAGGCAGGCAGTATCACTCA AGGCCACAGGTATTTTGTCG 219
IL-6 AACGATGATGCACTTGCAGA GAGCATTGGAAATTGGGGTA 285
IP-10 AAGTGCTGCCGTCATTTTCT CATTCTTTTTCATCGTGGCA 200
Irf1 GGAAGGGAAGATAGCCGAAG ACTCACTCAGGAGGGCAAGA 341
Irg1 CACTCTAAAGGACGGGACCA GGAGCAGGAAACCAAAACAA 337
M-CSF ATGGACACCTGAAGGTCCTG GCTGGAGAGGAGTCTCATGG 303
MIP-1 TTCTGTGCTCCAGGGTTCTC GAGGAGGCCTCTCCTGAAGT 282
PAI-1 ACGTTGTGGAACTGCCCTAC TTTTGCAGTGCCTGTGCTAC 306
RANTES CCCTCACCATCATCCTCACT CTTCTTCTCTGGGTTGGCAC 218
TNF CAGTTCTATGGCCCAGACCCT CGGACTCCGCAAAGTCTAAG 450
Ifit1 TGGCCGTTTCCTACAGTTTC GGAGCATTGGAACACTTGGT 329
Mlp TCTTGTGCTGTGCCTAGTGG GGGGTTTGGCCATTAAAAGT 233
Vig1-pending* AACCCCCGTGAGTGTCAACTA AACCAGCCTGTTTGAGCAGAA 140
Ifit3* AGTGAGGTCAACCGGGAATCT TCTAGGTGCTTTATGTAGGCCA 188
Tyki GGCAATTATCTCGTGGCTTC GGGTTCTCCATACGCTGGTA 334
-Actin TTGAACATGGCATTGTTACCAA TGGCATAGAGGTCTTTACGGA 675
*See Ref. 49.
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(0.005, 0.05, 0.5, 5 M), or infection with Sendai virus (0.1, 1, 10,
100 hemagglutination units/ml). Cell culture supernatants were re-
moved at 0, 1, 2, 4, 6, 8, and 24 h and analyzed for the presence of
TNF, IL-6, IL-12p40, granulocyte macrophage-colony stimulating
factor (GM-CSF), macrophage-colony stimulating factor (M-CSF),
RANTES, and IP-10 by ELISA according to the manufacturer’s
recommendations (R & D Systems, Minneapolis, MN).
Transcription factor binding site identification. The sequences of
genes represented on the microarrays, spanning the region from
1,000 bp upstream of the start site of transcription to 500 bp
downstream of that site, were downloaded from http://siriusb.
umdnj.edu:18080/EZRetrieve/index.jsp (55), and Repeat Masker
(http://www.repeatmasker.org/) was used to mask out repeats.
NF-B and interferon-stimulated response element (ISRE) sites
were defined by TRANSFAC 6.0 weight matrices (http://www.
gene-regulation.com), and a similarity scoring method was used to
find matching sequence sites. For each position along the sequence, a
match score to the weight matrix minus the minimal possible score
divided by the difference of the maximal score and the minimal
weight matrix score was calculated and multiplied by 100. A resulting
score larger than 85 was considered a match. One insertion (or
deletion) in the k 1 bases from the current position was allowed and
a match recorded if the calculated result score, excluding the inserted
(or deleted) position, was larger than 85.
Transfection assays. TLR-3-expressing HEK293 cells were seeded
into 96-well plates at a density of 1.5  104 cells/well and transfected
24 h later with 40 ng of the indicated promoter-luciferase constructs
and a thymidine kinase Renilla-luciferase reporter gene (TK-luc;
Promega) (40 ng/well) using GeneJuice (Novagen, Madison, WI).
Cells were also cotransfected with expression vectors for MyD88,
TRIF, p65, or IRF3–5D as indicated. After 24 h, cells were lysed and
reporter gene activity was measured using the Dual Luciferase Assay
System (Promega). Data were normalized to TK-luc and are expressed
as the mean stimulation  SD.
RESULTS
Role of MyD88 in TLR signaling. To examine the require-
ment for MyD88 in TLR signaling, we treated WT C57BL/6
and MyD88-deficient BMDMs with a variety of TLR agonists
at varying concentrations. The induction of TNF (reported to
be MyD88 dependent when activated by TLR-4; Ref. 23) and
RANTES (MyD88 independent; Ref. 10) were measured.
MyD88-dependent induction of TNF was observed in mac-
rophages upon treatment with LPS (TLR-4), Malp-2 (TLR-2),
CpG DNA (TLR-9), and R-848 (TLR-7) but not upon treat-
ment with the TLR-3 ligand poly I:C or following infection
with Sendai virus (Fig. 1A). The expression of RANTES was
impaired following stimulation with Malp-2, CpG DNA, or
R-848. In contrast, RANTES was induced normally following
poly I:C and LPS stimulation or infection with Sendai virus
(Fig. 1B). These findings suggest that both TLR-3 and TLR-4
signaling pathways have distinctive properties that distinguish
them from the other TLRs. TLR-3 signaling is unique among
TLRs in that it does not require MyD88, whereas TLR-4 can
employ both MyD88-dependent and -independent signaling
pathways.
LPS and E. coli elicit identical responses in murine macro-
phages. To delineate the role of MyD88 in TLR-4 signaling,
we used microarray analysis to examine the gene expression
profile of WT C57BL/6 and MyD88-deficient macrophages
following LPS and live E. coli stimulation. Four conditions
were tested: 1) WT BMDMs stimulated with LPS vs. controls
(medium only), 2) MyD88-null BMDMs stimulated with LPS
vs. controls, 3) WT BMDMs stimulated with living E. coli vs.
controls, or 4) MyD88-null BMDMs stimulated with living E.
coli vs. controls. A concentration of 10 ng LPS/ml was chosen
to approximate the endotoxin concentration encountered when
cells are treated with live E. coli bacteria at a density of 1
bacterium per macrophage. We found 1,055 genes (7.9% of the
13,369 genes represented on the array) to be significantly
induced or repressed (fold change 	 1; P 
 0.01; n  4;
Benjamini-Hochberg correction) in at least one of the four
conditions tested. The Benjamini-Hochberg correction, when
used at a significance level of P 
 0.01, predicts that only 1%
of the genes deemed significant by this test (
11 genes in this
experiment) can be expected to be false positives. The LPS-
and E. coli-induced gene expression profiles observed in WT
macrophages closely resemble previously published LPS- and
pathogen-induced gene programs in human macrophages and
dendritic cells (3, 17, 29, 30, 39). Among the most highly
responsive genes in our data set were cytokines, chemokines,
and other proinflammatory mediators, including TNF, IL-1,
IL-12p40, IL-6, Gro1, IP-10, MIP-1, MIP-1, RANTES, and
COX-2.
Next we compared the E. coli vs. the LPS response by
one-way ANOVA analysis. Surprisingly, only 13 genes (P 

0.01) responded differentially to the E. coli and the LPS
treatment among the 1,055 genes determined to be responsive
Fig. 1. Myeloid differentiation protein-88 (MyD88) plays a unique role in
Toll-like receptor-3 (TLR-3) and TLR-4 signaling. TNF (A) and RANTES
(B) were measured in supernatants by ELISA after stimulation for 24 h with
several different TLR agonists. The agonists used were the TLR-2 agonist
MALP2 (0.01, 0.1, 1, 10 nM), the TLR-3 agonists poly I:C (0.1, 1, 10, 100
g/ml) and Sendai virus (0.1, 1, 10, 100 hemagglutination units/ml), the
TLR-4 agonist lipopolysaccharide (LPS; 0.1, 1, 10, 100 ng/ml), the TLR-7
agonist R-848 (0.01, 0.1, 1, 10 M), and the TLR-9 agonist CpG DNA (0.005,
0.05, 0.5, 5 M).
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to either stimulus. This number nearly matches the number of
genes whose expression would be predicted to differ by chance
(11 genes), and thus it appears that the E. coli and LPS
stimulations produced virtually identical gene expression pro-
files. In Fig. 2D, the similarity in macrophage responses to LPS
and E. coli is depicted using a self-organizing map (SOM)
clustering algorithm (GEDI; Ref. 7) that graphically portrays
the expression of the 1,055 responsive genes.
MyD88-dependent, MyD88-independent, and “MyD88-
modulated” pathways mediate the LPS response. We next set
out to group genes based on their requirement for MyD88.
Genes can be either induced or repressed by LPS treatment, the
response can be either MyD88 dependent or independent, and
the MyD88 dependence can be directional: that is, the absence
of MyD88 can either increase or decrease the LPS response. To
populate these theoretical groups (illustrated in Fig. 2A), we
started by determining which genes were induced or repressed
following LPS stimulation in WT macrophages. For those
genes whose expression changed, we next determined whether
this change required MyD88 to be present. MyD88-dependent
genes were initially defined as those whose absolute change in
response to LPS was significantly reduced in the absence of
MyD88 (P 
 0.01, one-way ANOVA using Benjamini-Hoch-
berg correction). The expression of a few genes that failed to
reach this statistical measure of significance was noted to be
consistently different in WT and MyD88-deficient cells. In
Fig. 2. LPS signaling is mediated by MyD88-dependent, MyD88-independent, and MyD88-modulated pathways. The LPS
response in wild-type (WT) and MyD88-deficient macrophages was classified into seven theoretical groups (A), defined by the WT
response to LPS treatment (x-axis) and the MyD88 dependency of the response (y-axis). Fold changes in gene expression upon LPS
treatment were compared with mock treatment, assessed by microarray analysis (B). The LPS response consisting of MyD88-
dependent, MyD88-independent, and MyD88-modulated genes is dominated by MyD88-independent pathways. Percentages reflect
the number of genes in the category shown divided by the total number of genes that responded to LPS (C). A graphical mosaic
of LPS-responsive gene expression clusters produced by a self-organizing map algorithm (GEDI) illustrates the similarity of gene
responses to LPS and E. coli (D).
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order not to exclude these genes, we added a second criterion
by which a gene could qualify as MyD88 dependent. This
criterion required that the difference in expression between
MyD88-null and WT cells differed by 4-fold (average cal-
culated for n  4 replicates) upon LPS or E. coli treatment. In
total, nine genes, including IL-12p40, were added to the
MyD88-dependent gene list using this criterion (see P values
for IL-12p40 in Table 2).
In the statistical analysis, we also noted a small group of
genes that were significantly dependent on MyD88 but showed
increased induction (or repression) in the absence of MyD88,
rather than decreased induction, as might have been expected.
Hence, if the absolute response to LPS was greater in the
absence of MyD88, then the genes were classified as “MyD88
modulated” (Fig. 2, A and B). The remaining genes that were
LPS responsive, but neither dependent nor modulated by
MyD88 as defined above, were considered to be MyD88
independent.
About half of the genes were induced (507 genes of 1,055 or
48.1%) by LPS treatment and half were repressed. This 50%
ratio was largely preserved when broken down into the various
types of MyD88 responses as just defined (Fig 2A). However,
Table 2. Representative genes of the categorized LPS-induced gene program in macrophages
Gene
Fold Change
PMyD88
Fold Change
PCHX
WT
(n  8)
MyD88/
(n  8)
WT  CHX
(n  3)
LPS-induced genes (fold upregulated)
MyD88 dependent
Interleukin-1 73 (46–117) 9.3 (3.4–26) 
0.0001 36 (16–77) 0.047
Prostaglandin-endoperoxide synthase 2 (Cox-2) 58 (19–183) 3.1 (1.5–6.2) 0.00032 14 (7.7–25) 0.20
Chemokine (C-X-C motif) ligand 1 (CXCL1; KC; Gro1) 54 (27–107) 23 (11–45) 0.0067 69 (49–97) 0.69
Interleukin-1 45 (18–109) 8.9 (5.4–15) 
0.0001 29 (21–41) 0.57
Tumor necrosis factor 35 (21–57) 12 (9.5–15) 
0.0001 23 (12–43) 0.53
Serine (or cysteine) proteinase inhibitor, clade E, member 1 (Serpine1; PAI-1) 31 (15–62) 7.4 (5.1–11) 
0.0001 2.8 (1.2–6.5) 0.047
Chemokine (C-X-C motif) ligand 2 (MIP-2) 30 (21–42) 5.4 (3.2–9.1) 
0.0001 33 (20–54) 0.83
Chemokine (C-C motif) ligand 4 (MIP-1) 24 (13–43) 7.7 (4.6–13) 
0.0001
Interleukin-10 (IL-10) 23 (15–35) 5.4 (2.4–12) 0.00052 1.0 (0.8–1.2) 0.00023
Interleukin-12 (IL-12p40) 17 (8.5–34) 1.7 (0.2–13) 0.021
Interleukin-6 (IL-6) 15 (6.7–32) 0.00016
Colony stimulating factor 2 (granulocyte-macrophage) (Csf2; GM-CSF) 13 (6.3–25) 1.8 (1.3–2.3) 0.00044 2.8 (0.8–10) 0.39
MyD88 independent
Immunoresponsive gene 1 29 (21–39) 44 (31–62) 0.43 22 (12–41) 0.66
Chemokine (C-X-C motif) ligand 10 (IP-10) 26 (17–40) 37 (18–74) 0.99 30 (20–44) 0.78
Interferon regulatory factor 1 12 (9.3–16) 22 (13–38) 0.13 17 (15–20) 0.17
Mus musculus NIH 3T3 chemokine rantes (Scya5) gene, complete cds
(RANTES; CCL5) 15 (11–22) 19 (12–29) 0.48 6.6 (5.6–7.8) 0.028
Icos ligand (Icos1) 13 (8.4–20) 16 (11–25) 0.97 22 (19–26) 0.19
C-type lectin, superfamily member 9 (Clecsf9) 13 (8.8–20) 15 (11–19) 0.84 19 (11–33) 0.48
Tnf receptor-associated factor 1 (Traf1) 9.0 (5.0–16) 13 (6.4–28) 0.92 19 (17–21) 0.17
Interferon-induced protein with tetratricopeptide repeats 1 (Ifit1) 3.7 (2.1–6.6) 13 (6.8–25) 0.040 1.7 (1.4–2.1) 0.16
Colony stimulating factor 1 (macrophage) (Csf1; M-CSF) 11 (8.3–15) 12 (6.9–22) 0.39
MARCKS-like protein (Mlp) 6.4 (4.6–8.9) 11 (8.5–14) 0.21 7.3 (6.9–7.6) 0.63
MyD88 modulated
Viral hemorrhagic septicemia virus (VHSV) induced gene 1 3.4 (2.1–5.5) 17 (7.5–39) 0.00088 1.9 (1.1–3.5) 0.38
Toll-like receptor 2 (TLR-2) 5.6 (4.7–6.7) 8.3 (6.8–10) 0.0013 4.0 (3.1–5.2) 0.26
Thymidylate kinase homolog mRNA, complete cds (Tyki) 2.1 (1.4–3.3) 8.2 (6.0–11) 0.00080 1.3 (1.2–1.1) 0.36
Interferon-induced protein with tetratricopeptide repeats 3 (Ifit3) 1.7 (1.3–2.4) 4.4 (2.6–7.3) 0.0020 0.9 (0.8–1.1) 0.054
LPS-repressed genes (fold downregulated)
MyD88 dependent
Thioredoxin interacting protein 23 (49–10) 1.5 (1.9–1.2) 
0.0001 2.9 (3.9–2.2) 0.022
Lymphoblastomic leukemia 12 (23–5.9) 3.8 (4.3–3.3) 0.0056 1.7 (3.1–1.0) 0.031
RIKEN cDNA 2700062C07 gene 6.4 (8.1–5.0 3.2 (3.7–2.7) 0.00049 1.7 (2.2–1.2) 0.01
Isovaleryl CoA dehydrogenase putative (Ivd) 5.9 (7.4–4.7) 3.4 (4.0–3.0) 
0.0001 1.2 (1.4–1.0) 0.00070
MyD88 independent
Cannabinoid receptor 2 (macrophage) 43 (99–19) 14 (44–4.8) 0.18 1.5 (1.8–1.3) 0.0028
cDNA sequence BC003323 13 (28–6.4) 7.3 (11–4.9) 0.23 3.4 (5.8–2.0) 0.11
Hematopoietically expressed homeobox (Hhex) 12 (38–3.9) 6.7 (8.9–5.0) 0.16 1.5 (2.7–0.9) 0.074
MyD88 modulated
RIKEN cDNA 4933411B03 gene 1.9 (2.5–1.4) 3.5 (4.2–2.9) 0.0026 1.8 (2.8–1.1) 0.93
Bone marrow-derived macrophages (BMDMs) were treated with 10 ng/ml of lipopolysaccharide (LPS) for 2 h, and their gene expression profiles were
compared with that of mock-treated cells incubated for the same time using two-color oligonucleotide microarrays. Cells from four individual mice of each
genotype were used. Each mouse served as its own mock control, and expression was assayed in duplicate with reversal of the dyes used for labeling control
and stimulated samples (n  8 microarrays per genotype). Cells from three wild-type (WT) mice were treated with 10 ng/ml of LPS and 10 M cycloheximide
for 2 h. The data are reported as fold changes upon LPS treatment, compared with mock treatment. Average fold changes are followed by a 95% confidence
interval within parenthesis. Probability values for the effect of MyD88 deletion (PMyD88) and the effect of cycloheximide inhibition of the LPS response in WT
macrophages (PCHX) were calculated by t-test.
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those genes whose expression was induced had larger percent-
age changes in expression than the genes that were repressed
(note the distribution along the x-axis in Fig. 2B).
MyD88-independent gene expression dominates the LPS
response. Although recent studies (22, 24, 38) had prepared us
for the possibility that a few genes would not require MyD88
for their activation by LPS stimulation, we expected the num-
ber to be quite small and anticipated that those might be worth
analyzing by individual experimental interrogation. In contrast
to this prediction, 788 (74.7%) of the 1,055 genes that met our
criteria as LPS responsive were MyD88 independent. Only 227
(21.5%) genes were MyD88 dependent (Fig. 2C). The number
of MyD88-modulated genes was small (40 genes or 3.8%). A
striking feature of the data is the predominance of genes
induced or repressed to the same extent by LPS in WT and
MyD88-deficient cells. As our criteria for classification of
genes as MyD88 dependent were quite stringent, we thought it
possible that they might have led to the overestimation of the
genes classified as MyD88 independent. We therefore exam-
ined the levels of differential gene expression in the subset of
genes classified as MyD88 independent. This analysis demon-
strated that more than 82% of these genes had an average
LPS-stimulated expression level in the WT macrophages that
was 
30% different from the MyD88-deficient macrophages.
With current microarray methodology, expression differences
of this magnitude typically represent variability in the assay
measurement rather than significant differences in gene expres-
sion. Thus our finding of the predominance of MyD88-inde-
pendent gene expression in response to LPS stimulation is
unlikely to be a consequence of our choice of criteria in
defining MyD88 dependence. The predominance of MyD88-
independent gene expression is readily visualized in the GEDI
mosaic graph (Fig. 2D), where the majority of colorized
clusters persists in the MyD88-null cells compared with the
WT macrophages. Thus LPS induces a vast gene expression
program that is independent of MyD88 activity, although many
of the best characterized LPS responses do, in fact, require
MyD88.
MyD88-dependent pathways regulate many classic markers
of inflammation. The expression of many well-characterized
markers of inflammation, including IL-1, Cox-2, TNF, IL-
10, IL-12, and IL-6, required MyD88 for optimal expression
(Table 2). We measured the MyD88-dependent expression of
TNF, MIP-1, IL-1, PAI-1, Cox-2, and IL-10 using QRT-
PCR (Fig. 3A) to verify the microarray results. Simultaneous
measurement of the housekeeping gene, -actin, indicated no
change in its expression in the comparison of WT to MyD88-
deficient macrophages (Fig. 3B). The protein expression of
many of the MyD88-dependent inducible genes was also mea-
sured by ELISA, to further validate the RNA expression
results. As seen in Fig. 3C, TNF, IL-6, IL-12p40, and GM-
CSF production was severely attenuated in macrophages taken
from MyD88-deficient mice. Thus the microarray data for
MyD88-dependent expression of several of the most important
Fig. 3. QRT-PCR and protein expression
analysis of MyD88-dependent gene expres-
sion. Total RNA was isolated from macro-
phages 2 h after stimulation with 10 ng/ml
LPS or mock treatment. A: Total RNA from
four mice was pooled, and fold changes in
gene expression were determined in triplicate
by comparison to the mock-treated sample
using QRT-PCR. Since IL-1 expression
could not be detected by QRT-PCR in un-
stimulated cells, this level was assigned the
value of the lowest detection limit of the assay
to estimate an expression ratio. B: QRT-PCR
quantification of -actin in all the reverse-
transcribed total RNA samples used for nor-
malization of the data in A, and in Figs. 4A and
5A. C: supernatants were collected from mac-
rophages taken from two WT and two
MyD88-null mice and stimulated for the time
indicated with LPS, and TNF, IL-6, IL-
12p40, and GM-CSF levels were measured in
triplicate by ELISA. D: total RNA was iso-
lated from thioglycolate-elicited peritoneal-
exudate macrophages 2 h after stimulation
with 10 ng/ml LPS, and the fold change in
gene expression (compared to a mock-treated
sample) was quantified by QRT-PCR.
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macrophage inflammatory genes was confirmed using indepen-
dent measurements of both mRNA and protein production.
MyD88-independent pathways regulate known inflammatory
responses as well as many unknown genes. Several of the most
highly induced genes were found to be MyD88 independent
(Table 2). Some of these genes have previously been shown to
participate in the immune response, such as Irf1, IP-10,
RANTES, and M-CSF, and their expression was confirmed by
QRT-PCR (Fig. 4A). However, the functions of many of the
MyD88-independent genes are unknown. In the very large group
of genes determined to be MyD88 independent, only IP-10, Irg1,
IFN-, and Ifit1 have previously been reported to respond to LPS
stimulation via MyD88-independent signaling pathways (24).
Using QRT-PCR analysis, we verified the MyD88-independent
expression of several genes not previously known to fall into this
category, including Irf1, MARCKS-like protein (Mlp), and M-
CSF (Fig. 4A). ELISA analysis of RANTES and M-CSF estab-
lished that protein expression also mirrored the mRNA data for
MyD88-independent genes (Fig. 4B).
BMDMs were cultured in cytokine-rich medium for several
days prior to experimentation. The possibility existed that the
large number of genes expressed independently of MyD88
activity that we observed reflected the ex vivo maturation
conditions used in the culturing of the BMDMs. Thus we
measured the LPS-induced activation of two MyD88-depen-
dent genes (TNF and IL-1) and two MyD88-independent
genes (RANTES and Irf1) in thioglycolate-elicited peritoneal-
exudate macrophages by QRT-PCR to assess their dependence
on the macrophage preparative conditions (Fig. 3D and 4C).
Although the magnitudes of the MyD88-dependent gene re-
sponses were at least 10-fold higher in the peritoneal macro-
phages than in the BMDMs, the MyD88-dependent and -inde-
pendent classifications did not differ between these macro-
phage preparations.
MyD88-modulated genes reveal a novel regulatory function
of MyD88. A third group of genes identified in these experi-
ments were those whose expression was induced by LPS to
higher levels or repressed to lower levels in macrophages
Fig. 4. QRT-PCR and protein expression analysis of MyD88-independent gene expression. Total RNA was isolated from
macrophages 2 h after stimulation with 10 ng/ml LPS or mock treatment. A: total RNA from four mice was pooled, and fold changes
in gene expression were determined in triplicate by comparison to the mock-treated sample using QRT-PCR. B: supernatants were
collected from macrophages taken from two WT and two MyD88-null mice and stimulated for the time indicated with LPS, and
RANTES and M-CSF levels were measured in triplicate by ELISA. C: Total RNA was isolated from thioglycolate-elicited
peritoneal-exudate macrophages 2 h after stimulation with 10 ng/ml LPS, and the fold change in gene expression (compared to a
mock-treated sample) was quantified by QRT-PCR.
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lacking MyD88 activity. These we termed “MyD88 modu-
lated.” The modulation of viral hemorrhagic septicemia virus
(VHSV) induced gene 1 (Vig1-pending, also known as Viperin
and cig5), interferon-induced gene with tetratricopeptide re-
peats 3 (Ifit3), and thymidylate kinase (Tyki) was confirmed
using QRT-PCR (Fig. 5A). The QRT-PCR data suggests there
may be more MyD88-modulated genes than can be classified
using microarray data. Both Ifit1 and Irf1 were classified as
MyD88 independent because their expression levels did not
differ significantly, using our chosen cutoff value (P 
 0.01).
With QRT-PCR methodology, however, these would have
been categorized as MyD88 modulated (Fig. 4A and Table 2).
The existence of MyD88-modulated genes was further estab-
lished by measuring LPS induction in WT and MyD88-defi-
cient mouse embryonic fibroblasts (MEFs) by QRT-PCR (Fig.
5B). The LPS- and poly I:C-induced response was greater in
MyD88-deficient MEFs compared with MyD88-containing
MEFs. Both IL-6 and RANTES protein expression measured
by ELISA were induced by LPS in WT MEFs (data not
shown).
Although the MyD88-modulated gene group comprised only
a small percentage (3.8%) of the LPS-responsive genes on the
arrays, they provided an insight into a potentially novel
MyD88 function. This function can be viewed as constraining
the responsiveness of genes (either induction or repression) to
endotoxin stimulation. To investigate whether MyD88 modu-
lation also occurs downstream of TLR-3, a Toll receptor whose
signaling appears to be entirely dependent on the expression of
TRIF, we treated WT and MyD88-deficient MEFs with the
double-stranded RNA mimetic poly I:C for 2 h and assayed the
induction of MyD88-modulated genes by QRT-PCR (Fig. 5B).
The expression of Vig1-pending, Ifit3, and Tyki was increased
in the absence of MyD88 after poly I:C stimulation, suggesting
that MyD88 may also influence the expression of genes in-
duced by the TLR-3 pathway.
MyD88-independent gene expression does not depend on
new protein synthesis. Interferon-responsive genes (IRGs) are
components of an anti-viral signaling cascade shared by TLR-3
and TLR-4 and are regulated, in part, by the transcription
activator, interferon regulatory factor (IRF)-3 (4). The type I
interferon IFN- is an example of one such gene, whose
expression can activate a second wave of gene expression via
the type I interferon receptor and the JAK/STAT pathways (4,
45). As only one (myxovirus resistance protein 1; PMyD88 
0.0013) of 19 LPS-responsive genes annotated as viral re-
sponse genes or IRGs was MyD88 dependent, we wondered
whether the induction of many of the MyD88-independent
genes could be explained by secondary transcriptional events
that were dependent on the generation of protein produced in
the initial wave of gene induction. To test this possibility, WT
macrophages were treated with LPS in the presence of 10 M
of the protein synthesis inhibitor cycloheximide (26). Analysis
of this issue was limited to genes whose average expression
changed at least fourfold or more in response to LPS, as
determined in three or more independent microarray experi-
ments. Genes were deemed cycloheximide sensitive if the
induction by LPS alone or by LPS plus cycloheximide was
significantly different (t-test; P 
 0.05). Furthermore, gene
repression, should it exist for a given gene or set of genes, is
often reduced or eliminated by cycloheximide treatment as
transcripts become protected from degradation, resulting in
enhanced stability of mRNAs (26). We found that the majority
of those genes whose expression was repressed by endotoxin
were not repressed in the presence of cycloheximide (15 of 18
genes or 83%; Table 2). In contrast, the majority of those genes
that were upregulated after LPS stimulation were not sensitive
to cycloheximide (65 of 97 genes or 67%; Table 2). MyD88-
independent genes still constituted the majority of LPS-respon-
sive genes in the cycloheximide-treated cells (41 of 65 genes or
63%), establishing that MyD88-independent signaling does not
simply reflect widespread secondary transcriptional events.
These data confirm previous studies by others showing that
IP-10 and Irf1 are primary response genes (4, 12) and classifies
the expression of several other genes as part of a primary or
secondary response pathways (Table 2).
Vig1-pending and other genes not requiring MyD88 for
maximal induction are regulated by concordant NF-B and
IRF-3 activation. We were particularly interested in MyD88-
independent antiviral response genes such as RANTES, IP-10,
and Ifit1, which can be activated without new protein synthesis
and are known to be induced by coordinate IRF-3 and NF-B
activation. This suggested that the presence of IRF-3 and
NF-B transcription factor binding sites might represent a
signaling module activating at least a subset of the MyD88-
Fig. 5. QRT-PCR expression analysis of MyD88-modu-
lated genes. Total RNA was isolated from macrophages 2 h
after stimulation with 10 ng/ml LPS or mock treatment.
The fold change in gene expression was determined by
comparison to the mock-treated sample using QRT-PCR
(A). Total RNA was isolated from mouse embryonic fibro-
blasts (MEFs) 2 h after stimulation with 100 ng/ml LPS (B)
and 100 g/ml poly I:C (C), and the fold change in gene
expression (compared to a mock-treated sample) was quan-
tified by QRT-PCR
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independent genes. Hence, we examined the promoter regions
of all of the genes arrayed on our slides for both NF-B and
IRF transcription factor binding sites. The known IRF-3/
NF-B response genes (RANTES, IFN, IP-10, and Ifit1)
contained both ISRE and NF-B sites within 300 bp of the
transcription start site and no greater than 100 bp apart from
each other. In addition, Irg1, Vig1-pending, and Ifit3, which
respond robustly to LPS, share these same tandem site char-
acteristics, suggesting that they are also regulated by concor-
dant IRF-3 and NF-B activation (Fig. 6A).
To explore the concordant IRF-3 and NF-B activation
further, we examined the inducibility of the Vig1-pending
promoter, a gene strongly induced by LPS, in HEK293 cells
expressing TLR-3. As seen in Fig. 6B, two strong activators of
NF-B, IL-1 and TNF, both failed to induce Vig1-pending
reporter gene activity. In contrast, stimulation of cells with
poly I:C or infection with Sendai virus, which activate both
NF-B and IRF-3, strongly induced reporter gene activity,
suggesting that activation of NF-B alone is insufficient to
induce Vig1-pending promoter activation. Recently the TIR
domain-containing adapter molecules TRIF and TRAM have
been shown to regulate MyD88-independent gene expression
via IRF-3. Overexpression of either of these two adapters or
MyD88 results in the activation of their downstream signal
transduction pathways (8). We examined the ability of either
MyD88 or TRIF to activate the Vig1-pending reporter gene
(Fig. 6C) in transfected HEK293 cells. Overexpression of
MyD88 did not induce Vig1 promoter activity, whereas over-
expression of TRIF induced a vigorous Vig1 promoter re-
sponse. Vig1 promoter activity was also induced by the con-
stitutively active IRF3–5D mutant (Fig. 6D), but not by the p65
subunit of NF-B, again suggesting that activation of NF-B
alone is insufficient to drive this promoter. This is in agreement
with the inability of either IL-1 or TNF to induce Vig1, as
Fig. 6. A: Vig1-pending is activated by NF-B and IRF-3. Schematic representation of NF-B and ISRE transcription factor
binding sites in LPS-induced genes. B: TLR-3-expressing HEK293 cells were transfected with luciferase reporter genes under the
control of Vig1-pending and NF-B promoters and activated by IL-1, TNF, Sendai virus, and poly I:C. C: Vig1-pending and
NF-B promoter activation when cotransfected with MyD88 or TRIF. D: Vig1-pending and NF-B promoter activation when
cotransfected with constitutively active IRF-3 or p65.
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these cytokines activate NF-B but will not activate reporter
gene expression from an ISRE. Furthermore, the induction of
Vig1 by TRIF was inhibited by coexpression of dominant-
negative forms of both NF-B and IRF signaling (the IB
super-repressor or IRF-3 dominant negative) (data not shown).
Taken together, these observations confirm that the MyD88-
independent pathway regulator, TRIF, induces Vig1 and that
expression of Vig1 requires activation of both NF-B and
IRF-3. Although several MyD88-independent genes contained
NF-B and ISRE binding sites, and are likely critical early
mediators of MyD88-independent signaling events, it is clear
that additional signaling pathways remain to be identified that
would account for the expression activity of the large number
of MyD88-independent genes that apparently lack proximal
ISRE binding sites.
DISCUSSION
The present study illustrates the use of expression profiling
to compare and classify the LPS response in cells that do and
do not express critical mediators of that response. This study
has some inherent limitations that must be recognized. To
conduct these experiments, it was necessary to select a single
time point to perform the comparison. As previous work has
indicated that LPS responses can be delayed rather than lost in
mice lacking key mediators in the TLR pathway (23), our
classifications of genes as MyD88 dependent or independent
are necessarily limited to the time course we have chosen. To
fully understand the complex signaling network induced by
LPS over time, additional time course experiments will be
required. In addition, our understanding of the transcriptional
regulation of this gene network is quite rudimentary, making it
unwise to generalize from the limited Vig1-pending transcrip-
tional analysis undertaken here.
In view of the toxicity of gram-negative bacteria, it is not
surprising that LPS activates such a rich gene expression
program (1,000 genes or almost 8% of the genes probed in
this experiment), all of which are likely induced via TLR-4.
The data presented here show that LPS and E. coli induce
almost identical gene expression profiles, suggesting that the
contribution of TLRs other than TLR-4 to the E. coli response
is either minor or overlapping with the TLR-4 response. The
data are the latest confirmation of a long-held (but nevertheless
controversial) dogma, i.e., that the LPS portion of the outer
leaflet of gram-negative bacteria is the predominant activator
of the innate immune system. In this respect, the influence of
endotoxin appears to be far greater than other cell wall con-
stituents, including immunologically important molecules such
as lipopeptide, peptidoglycan, and flagellin.
MyD88-deficient mice do not need to be housed in a patho-
gen-free environment to survive and have been shown to
mount a host defense response to polymicrobial peritonitis (51)
and local Staphylococcus aureus infection, despite blunted
cytokine responses (41). This suggests that MyD88-indepen-
dent signaling pathways play important roles in the control of
endogenous host microflora as well as in the defense against
some virulent pathogens. However, MyD88-deficient mice are
more vulnerable to certain infections, such as systemic chal-
lenge with S. aureus (46), Listeria monocytogenes (6), and
Pseudomonas aeruginosa (41), indicating that MyD88 plays a
vital role in normal host defense against important pathogens.
The genes downstream of the NF-B pathway are clearly
critical to this host defense response and were clearly dysregu-
lated in the absence of MyD88.
NF-B, JNK, and p38 MAPK are essential for the induction
of TNF and are activated downstream of MyD88 (40, 42). In
MyD88-deficient cells, NF-B, JNK, and p38 MAPK all ex-
hibited delayed activation. The lack of LPS-inducible TNF
protein production in MyD88-null cells may be due to this
delayed activation, although it is difficult to understand how
the modestly altered kinetics of these responses might translate
into such a profound defect in protein production, especially
when so many other LPS responses are entirely intact. Alter-
natively, MyD88 might regulate an unknown key factor essen-
tial for TNF transcription, mRNA stabilization, translation, or
secretion. It should also be noted that not all reports (47) have
shown the same failure of MyD88-deficient macrophages to
secrete cytokines in response to LPS as presented here and
elsewhere (23). Our data also suggest that results obtained in
macrophages from different sources by different experimental
protocols may not always be directly comparable. The use of
thioglycolate to elicit the macrophage exudate in the perito-
neum may result in cells that are primed to be more responsive
to subsequent inflammatory stimuli. Such sensitization has
been observed, for instance, for IL-6 production in macro-
phages when primed with either low doses of LPS (13) or
M-CSF (43).
To avoid detrimental uncontrolled inflammation, the innate
immune response must constantly strike a balance between
activation and inhibition. Following LPS stimulation, macro-
phages enter a transient state where a second LPS stimulus is
blunted or absent. This so-called “endotoxin tolerance” sug-
gests that inhibitory pathways may become activated that
downregulate the LPS response. The “MyD88 modulation”
phenomena described herein may reflect a requirement for
MyD88 in this attenuation response. MyD88 could directly
inhibit LPS activation pathways or alternatively could be
required for the induction of an inhibitory molecule. Recently
a number of negative regulators of LPS signaling have been
described that could modulate expression by either of these
mechanisms. These proposed negative regulators, including a
short splice variant of MyD88 (MyD88s) (20), Irak-M (25),
SOCS-1 (28), PI3K (11), and the TIR domain containing
receptors T1-ST2 (44) or SIGGIR (48). These proteins repre-
sent attractive candidates responsible for the MyD88 modula-
tion observed in this study.
Our study suggests that the majority (3/4) of the host
response to LPS is regulated independently of MyD88 and that
this response involves a diversity of host activities in addition
to the well-characterized type I interferon response. LPS sig-
naling appears to uniquely utilize all four of the known TIR
domain-containing adapter molecules [MyD88, Mal (also
known as TIRAP) (9, 16), TRIF (also known as TICAM-1)
(33, 54), and TRAM (also known as TIRP/TICAM-2) (2, 10,
34, 53)] to activate its full transcriptional response. Published
reports indicate that TRAM may be the “master adapter” for
LPS responses (53). TRAM contains an N-myristoylation site
that targets this adapter to TLR-4 in resting cells (D. C. Rowe,
K. A. Fitzgerald, D. T. Golenbock, unpublished observations).
Both targeted deletion and small interfering RNA (siRNA)
silencing experiments have demonstrated a nearly absolute
requirement for TRAM in the TLR-4 pathway (10, 53).
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In contrast to MyD88 and Mal, which are thought to func-
tion as a heterodimer to regulate MyD88-dependent pathways,
TRIF seems to bridge both MyD88-independent and MyD88-
dependent pathways. TRIF-deficient (52) and TRIF-mutant
mice (15) fail to induce IFN, IP-10, Irf1, RANTES, TNF,
IL-6, and IL-12p40. TRIF has been shown to interact with
TRAF6, a component of the MyD88-dependent pathway that
activates NF-B and controls the expression of genes such as
TNF and IL-6 (21, 37). A recent study from Holzmann and
coworkers (50) examining the gene expression profile follow-
ing LPS stimulation in dendritic cells taken from mice carrying
a loss of function mutation in TRIF found that 50% of the
LPS response was dependent on TRIF. Genes appearing to be
TRIF dependent are classified as both MyD88-independent and
MyD88-dependent genes in our study, consistent with the
ability of TRIF to bridge both MyD88-independent and
MyD88-dependent pathways.
A genome-wide approach will be critical to defining the
individual contribution, and possible redundancy, of the dif-
ferent adapter molecules and pathways to the LPS-induced
response in immune cells. Once established, the differences in
adapter molecule utilization can be exploited for the rationale
design of anti-inflammatory therapies that inhibit certain sub-
sets of deleterious inflammatory responses while leaving host
defense mechanisms intact. The data we report here provide an
initial roadmap to defining the adaptor specificity of the host
innate immune response.
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